Image

Global Mitotic Inhibitors Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Mitotic Inhibitors Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Mitotic Inhibitors Market  , By Indication (Breast CancerLung CancerBlood Cancer, Others), Drug Class (Taxanes, Vinca Alkaloids, Colchicine, Podophyllotoxins, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Mitotic Inhibitors Market

Mitotic Inhibitors Market Analysis and Size

The global mitotic inhibitors market is expected to witness significant growth during the forecast period. The factors that boosted the growth of mitotic inhibitors market are increasing cases of cancer such as lung cancer and breast cancer and aging population. These are used to treat several types of cancer using chemotherapy. These drugs are largely targeted at cancer cells to stop multiplication and help to eradicate cancer. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global mitotic inhibitors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

A mitotic drug is a type of pharmaceutical drug that blocks cell growth by restricting the cell division or mitosis. In addition to this, these drugs act by interfering with microtubules, which is a receptor that is responsible for pulling the cell apart when it split. It is extensively used in cancer treatment, especially for breast cancer patients.

Mitotic Inhibitors Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Indication (Breast Cancer, Lung Cancer, Blood Cancer, Others), Drug Class (Taxanes, Vinca Alkaloids, Colchicine, Podophyllotoxins, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Takeda Pharmaceutical Company Limited (Japan), Akorn, Incorporated (U.S.) Torrent Pharmaceuticals Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.)

Market Opportunities

  • Increased Investments and Development
  • Increasing Demand for Retail Pharmacies

Global Mitotic Inhibitors Market Dynamics

Drivers

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as many of the products are available in capsule and tablet form and it is a very feasible route of administration.

  • Increasing Prevalence of Breast Cancer

The rising cases of breast cancer across the world in the developed as well as under-developed countries boosts the global adrenal corticosteroid inhibitor drugs market. As per the reports of WHO, 58% of deaths caused by breast cancer mostly occur in under-developed or developing countries in the world.

Opportunities

  • Increased Investments and Development

Several mitotic inhibitors are extensively used in life sciences for numerous studies such as study of chromosomes (cytogenetic). Numerous market players are investing in developing and commercializing mitotic inhibitor drugs to treat cancer patients and other medical conditions. Natural occurrence and efficiency to treat cancer are likely to increase the uptake of these drugs during the forecast period.

  • Increasing Demand for Retail Pharmacies

The increase in the number of cancer patients led to the increase in mitotic inhibitors that are being delivered through retail pharmacies and increase in the number of retail pharmacies in developed countries create opportunities for market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are more convenient.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global mitotic inhibitors market over a forecast period.

  • High Cost

The huge expenditure associated with mitotic inhibitors surely hamper the market growth.

This global mitotic inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mitotic inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Mitotic Inhibitors Market

COVID-19 has left a major global public health crisis which has impacted practically every business. Shift from healthcare infrastructure towards managing COVID-19 has led to drug launch withdrawals and delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are estimated to witness enormous future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will significantly impact the global mitotic inhibitors market.

Global Mitotic Inhibitors Market Scope

The global mitotic inhibitors market is segmented on the basis of indication, drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Breast Cancer
  • Lung Cancer
  • Blood Cancer
  • Others

Drug Class

  • Taxanes
  • Vinca Alkaloids
  • Colchicine
  • Podophyllotoxins
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Mitotic Inhibitors Market Regional Analysis/Insights

The global mitotic inhibitors market is analysed and market size insights and trends are provided by type, drug class, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global mitotic inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global mitotic inhibitors market throughout the forecasted period due to the high prevalence of cancer and increased number of FDA-approved drugs.

Asia-Pacific dominates the market due to the emerging healthcare facilities, a greater number of generic manufacturer and increase in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Mitotic Inhibitors Market Share Analysis

The global mitotic inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mitotic inhibitors market.

Key players operating in the global mitotic inhibitors market include:

  • Novartis AG (Switzerland)
  • Endo International Inc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Glenmark Pharmaceuticals Ltd (India)
  • Cipla Inc (India)
  • Dr Reddy's Laboratories Ltd (India)
  • Abbott (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Pfizer Inc (U.S.)
  • Zydus Group (India)
  • Lupin (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Akorn, Incorporated (U.S.)
  • Torrent Pharmaceuticals Ltd. (India)
  • Amneal Pharmaceuticals LLC. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Mitotic Inhibitors Market soars a healthy CAGR forecast by 2029.
Its fragmented by indication, drug class, route of administration, end-users & distribution channel
The factors such as the rising demand for oral drugs and the increasing prevalence of breast cancer are acting as the major drivers for the global mitotic inhibitors market.
The major companies operating in the Mitotic Inhibitors Market are Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr. Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Takeda Pharmaceutical Company Limited (Japan), Akorn, Incorporated (U.S.), Torrent Pharmaceuticals Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials